Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After cancer: Study explores caring-healing modalities for survivors

2.

Study offers clearer picture of childhood brain tumor survival

3.

How AI will transform mental health support for patients with breast cancer

4.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

5.

Rural residents continue to have higher odds of skin cancer, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot